Results 211 to 220 of about 1,379,490 (255)

Engineered Xenogeneic Bone Scaffold with IL‐10 Nanodelivery System: Immunomodulation and BMSC Fate Programming for Skull Defect Repair

open access: yesAdvanced Science, EarlyView.
A multifunctional regenerative composite is constructed by 3D‐printing thermosensitive PNIPAM hydrogel embedded with MPDA@IL‐10 nanoparticles and autologous BMSCs onto antigen‐depleted porcine bone matrix for beagle critical‐sized skull defect reconstruction.
Weihao Lv   +16 more
wiley   +1 more source

ATL2 Recruits TRAK1 to Promote Mitochondrial Transport at ER–Mitochondria Contact Sites

open access: yesAdvanced Science, EarlyView.
ABSTRACT Mitochondrial transport and distribution are crucial for cellular homeostasis, yet whether and how they are regulated by endoplasmic reticulum (ER)–mitochondria contact sites remains unclear. Here, we demonstrate that the ER protein atlastin‐2 (ATL2) orchestrates mitochondrial transport and distribution by promoting assembly of the transport ...
Yiru Cheng   +9 more
wiley   +1 more source

TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers

open access: yesAdvanced Science, EarlyView.
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei   +10 more
wiley   +1 more source

Nanoparticle‐Mediated TIPE1 mRNA Delivery Enhances Paclitaxel Sensitivity in Triple‐Negative Breast Cancer by Modulating RAB7A Ubiquitination‐Associated Stability and Autophagy

open access: yesAdvanced Science, EarlyView.
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu   +9 more
wiley   +1 more source

Copper‐Doped Prussian Blue Nanozymes With Hyaluronic Acid‐Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy

open access: yesAdvanced Science, EarlyView.
CuPB@HA is a CD44‐associated, plaque‐targeted nanozyme that alleviates oxidative stress, inflammation, and lipid accumulation in macrophages. By reducing CD36‐dependent lipid uptake and promoting ABCA1/ABCG1‐mediated cholesterol handling, it improves macrophage function, preferentially accumulates in atherosclerotic lesions, reduces plaque burden, and ...
Jianliang Ou   +14 more
wiley   +1 more source

Continuous cell flocculation for recombinant antibody harvesting. [PDF]

open access: yesJ Chem Technol Biotechnol, 2018
Burgstaller D   +7 more
europepmc   +1 more source

DDX3x Regulates NINJ1 Transcription via Histone Lactylation in Sepsis Associated‐Acute Kidney Injury

open access: yesAdvanced Science, EarlyView.
This study identifies a potential therapeutic approach for sepsis‐associated acute kidney injury (SA‐AKI). We found that during SA‐AKI, reduced expression of DDX3x in renal tubular epithelial cells mediates histone delactylation, which in turn upregulates NINJ1 transcription and triggers tubular cell death. Conversely, Odetiglucan confers protection by
Hongyu Liang   +7 more
wiley   +1 more source

Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation

open access: yesAdvanced Science, EarlyView.
HOXC11 drives colorectal cancer progression by transcriptionally activating CAMK2A, which triggers NF‐κB–dependent CXCL5 upregulation. CXCL5–CXCR2 signaling further reinforces HOXC11 expression through the ERK1/2–SP1 axis, forming a prometastatic positive feedback loop that is effectively disrupted by combined CAMK2A and CXCR2 inhibition.
Qingyang Sun   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy